Resverlogix (TSX:RVX, StockForum), a Calgary-based clinical stage cardiovascular company engaged in the development of compounds involving a therapeutic increase in ApoA-I, announced phase 2b SUSTAIN and ASSURE trial results for their BET-inhibitor, RVX-208.
A independent third party firm carried out the analysis on atherosclerotic patients with high risk for recurrent events in order to determine potential benefits of RVX-208 in major adverse cardiac events (“MACE”) over a short term period of six months.
According to the news release, “When MACE data (n=499) from both SUSTAIN and ASSURE trials were combined, it demonstrated that treatment with RVX-208 lead to a significant reduction in MACE.”
It went on, “Furthermore, in patients who had elevated CRP > 2.0mg/dL (n=283) the benefit of RVX-208 treatment of patients (n=179) appeared more striking with a cumulative event rate of 6.42% vs. 20.53% (p=0.007) in the placebo group (n=104).”
President and CEO of Resverlogix, Donald McCaffrey described the importance of these findings, “A reduction in MACE will be a critical factor for registration of RVX-208. This analysis provides important information that RVX-208 when used in high risk atherosclerosis patients improves the most central measurement of all, the reduction of MACE in back to back trials.”
Dr. Jan Johansson, Senior Vice President of Medical Affairs at Resverlogix, summed up, “This early data is valuable to have as it illustrates in a cumulative fashion that RVX-208 has the potential to really impact cardiac events in those patients who are at very high risk.”
Resverlogix was in the news recently when the company was recognized in an industry publication for RVX-208.
Shares climbed 45.45% on the news to $0.80 per share.
Currently there are 81.7m outstanding shares with a market cap of $65.4 million.